Business Wire

CIRIUM

16.1.2024 10:01:26 CET | Business Wire | Press release

Share
Indian Airports Dominate Cirium’s 2023 On-Time Performance Review

Two of the top five global airports for on-time performance hailed from India this year, in Cirium’s annual On-Time Performance Review.

Rajiv Gandhi International Airport came second in the global rankings with 84.42% of flights on time, and Kempegowda International Airport hot on its heels with 84.08% of flights on time, in third place.

There was also a top place finish in the medium airports category for another APAC airport, with Osaka International Airport who managed an impressive 90.71% of flights on time. There was a second-place finish in the small airports category for Chubu Centrair International Airport (NGO) with 90.17% of flights on time, just 0.12% behind the top spot.

It should also be noted that Indigo Airlines was achieved an impressive fourth place in punctuality for the Asia Pacific Airline category with 82.12% of its flights arriving on-time. While operating nearly 680,000 flights in 2023.

An on-time flight is defined as a flight that arrives within 15 minutes of the scheduled gate arrival. For an airport, it is defined as departing within 15 minutes of its scheduled departure.

Jeremy Bowen, CEO of Cirium, said: "Cirium’s annual On-Time Performance Review is a global assessment of the punctuality of all types of carriers and airports, as evidenced by the widespread representation of operations from each corner of the globe, in this year’s review. Indian airports performed particularly well, with podium finishes in the global and large airport categories, and there was further representation for the APAC region in the other two airport categories as well. I’d like to extend my congratulations to all the featured airlines and airports in this year’s review.”

Now in its 15th year, the Cirium On-Time Performance program continues to meticulously monitor global airline operational performance. Our extensive and unbiased data, derived from over 600 real-time information sources, is essential for industry stakeholders. Our data encompasses airlines, airports, global distribution systems, civil aviation authorities, and more, ensuring a comprehensive and neutral perspective.

Cirium is continuing to lead the way, worldwide, in monitoring aviation on-time performance in the New Year, as the industry adjusts to post-pandemic norms. The company’s data and analytics are designed to provide industry stakeholders with a neutral, third-party perspective, based on the widest and deepest pool of information collected and curated from more than 600 sources of real-time flight information.

These include the airlines themselves, airports, global distribution systems, positional data, civil aviation authorities, air navigation service providers, proprietary data partnerships and the internet. Cirium’s on-time performance data is backed by a completely independent board of advisors, comprised of industry experts with an unbiased view of the aviation sector. The board’s oversight ensures accuracy and proper representation of all the information the company presents.

The top performing global airports of 2023 were:

Airport

On time ranking

On time departure

Total flights

Minneapolis-St. Paul International Airport (MSP)

1

84.44%

289,817

Rajiv Gandhi International Airport (HYD)

2

84.42%

168,426

Kempegowda International Airport (BLR)

3

84.08%

237,461

El Dorado International Airport (BOG)

4

84.01%

292,486

Salt Lake City International Airport (SLC)

5

83.99%

226,705

The top Asia Pacific Airlines of 2023 were:

Airline

On time ranking

On time arrival

Total flights

All Nippon Airways (NH)

1

82.75%

302,279

Japan Airlines (JL)

2

82.58%

308,302

Thai AirAsia (FD)

3

82.52%

113,871

IndiGo (6E)

4

82.12%

678,446

Air New Zealand (NZ)

5

79.68%

175,876

The full 2023 On-Time Performance Review is available for download at Cirium.com/on-time-performance

About Cirium

Cirium is the world’s most trusted source of aviation analytics. Through powerful data and analytics, coupled with decades of industry experience, Cirium is enabling airlines, airports, travel companies, aircraft manufacturers, and financial institutions, amongst others, to make intelligent and informed decisions that improve operations, grow revenues, and enhance customer experiences.

Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium updates on LinkedIn or visit www.cirium.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240116289335/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye